Facebook iconTwitter icon
Drivers of Type 2 Diabetes, October 7-11, 2018, Seoul, South Korea
Keystone Symposia is very pleased to hold our second rare disease conference and our first conference in a series of annual conferences to be held in beautiful Vienna, Austria, developed in collaboration with Vienna BioCenter Research Institutes GMI, IMBA, IMP and MFPL. 

Work over the past 30 years has resulted in the identification of genes for approximately 50% of the estimated 7,000 rare genetic diseases, and 500 medicinal products are currently on the market for rare diseases. It is predicted that most of the remaining disease genes will be identified in the next 10 years. The accelerating pace of rare disease gene identification means, in effect, an almost commensurate increase in molecularly defined, readily diagnosable, but nonetheless poorly understood and untreatable diseases. The three-day conference will:
  • Examine the current and future bottlenecks to gene discovery, disease modeling and therapeutic approaches for the estimated 7,000 known rare diseases;
  • Explore platforms for enabling global cooperation and data sharing to address the grand challenges of rare diseases;
  • Bring together diverse stakeholders (clinicians, basic scientists, industry, government, patient advocates), as well as students and post-doctoral fellows, to forge cross-disciplinary, international collaborations to advance rare disease research and therapy.

The conference will feature the following confirmed invited speakers (additional short talk speakers will be added, chosen from abstracts):
Diego Ardig˛, Chiesi Farmaceutici, Italy
Jasmin Barman-Aks÷zen, Municipal Hospital Triemli, Switzerland
Lisa Bastarache, Vanderbilt University Medical Center, USA
Kym Boycott, CHEO Research Institute, Canada
Kaan Boztug, Ludwig Boltzmann Institute for Rare and Undiagnosed Diseases, Austria
Silvia Cappello, Max Planck Institute of Psychiatry, Germany
Helene Cederroth*, Wilhelm Foundation, Sweden
Michele De Luca*, University of Modena and Reggio Emilia, Italy
Christiane Druml, Medical University of Vienna and Ludwig Boltzmann Institute for Rare and Undiagnosed Diseases, Austria
William A. Gahl, NHGRI, National Institutes of Health, USA
Petra Kaufmann, AveXis, Inc., USA
Christoph Klein, Ludwig-Maximilians-University Munich, Germany
JŘrgen A. Knoblich, IMBA, Institute of Molecular Biotechnology, Austria
Michael J. Lenardo, NIAID, National Institutes of Health, USA
Malin Parmar, Wallenberg Neuroscience Center, Sweden
Sergiu Pasca, Stanford University, USA
Josef M. Penninger, Institute of Molecular Biotechnology GmbH, Austria
April Pyle, University of California, Los Angeles, USA
Bruno Reversade, Institute of Medical Biology, A*STAR, Singapore
Botond Roska, Friedrich Miescher Institute, Switzerland 

*Keynote speaker

Developed in collaboration with:
From Rare to Care: Discovery, Modeling and Translation of Rare Diseases
November 11?14, 2018
Vienna BioCenter
IMP Lecture Hall
Vienna, Austria

Josef Penninger, Institute of Molecular Biotechnology GmbH, Austria
Kym Boycott, CHEO Research Institute, Canada

ScholarshipApply for   
Submit AbstractSubmit   


? Approaches to Discover the Causes of all Rare Diseases

? Organoids to Model Rare Disease

? Therapeutic Approaches to Rare Diseases

? Translation of Discoveries to Treatments for Immunological Disorders

? Discovery to Mechanism to Therapy for Rare Diseases

? The Future of Rare Diseases


Who should attend?
Biotechnologists ? Clinicians ? Developmental Biologists ? Disease Modelers ? Drug Developers ? Geneticists ? Immunologists ? Neuroscientists ? Regulatory Scientists ? Stem Cell Biologists

Additional Information
  • Click here to view the program and click here to download the program flyer.
  • Deadlines are at midnight US Mountain Time.
  • Scholarships are for graduate students and postdocs and fund reimbursement of up to 1,200 USD in conference-related costs.
  • Discounted abstract submission saves 50 USD and discounted registration saves 200 USD on the later fees.
  • Presenting a poster is an excellent way to gain feedback on your work. Abstracts submitted by the August 13 abstract deadline will be considered for short talks on the program.
  • Please note that the first advertised meeting date is the date of arrival and registration, and the last date that of the last organized sessions.


Update your account details | Unsubscribe

Keystone Symposia on Molecular and Cellular Biology is a 501(c)(3) nonprofit organization headquartered in Colorado, USA that is directed and supported by the scientific community.
160 US Highway 6, Suite 200 | PO Box 1630 | Silverthorne, CO 80498 | USA
1-970-262-1230 | 1-800-253-0685 (in US & Canada)